Testosterone therapy and secondary erythrocytosis

Joshua White, Francis Petrella, Jesse Ory

Research output: Contribution to journalReview articlepeer-review


Secondary erythrocytosis is one of the most common adverse events associated with testosterone therapy (TT). Upon encountering this, clinicians will often either adjust TT dosing, stop therapy, order a phlebotomy, or recommend a combination of these. Despite this, the evidence for secondary polycythemia causing harm during TT is scarce, and the hematocrit-based cutoffs present in multiple guidelines appear to be arbritrarily chosen. In this review, we present the pathophysiology behind TT and secondary erythrocytosis, the evidence connecting TT, secondary erythrocytosis and major adverse cardiovascular events (MACE), and the data supporting varying interventions upon diagnosis of secondary erythrocytosis.

Original languageEnglish (US)
JournalInternational Journal of Impotence Research
StateAccepted/In press - 2022
Externally publishedYes

ASJC Scopus subject areas

  • Urology


Dive into the research topics of 'Testosterone therapy and secondary erythrocytosis'. Together they form a unique fingerprint.

Cite this